Clinical trials: Hepatitis C, completed
Hepatitis B
Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection
Background: Treatment of some diseases can suppress the immune system. This can cause other conditions to reactivate. Recent cases have shown that hepatitis B virus (HBV) reactivates in people who had already recovered from it…
- Trial name
- NCT03248622
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatocellular Carcinoma, Ablation
Ablation of Hepatocellular Carcinoma: a Nationwide Study
Background Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver. Chronic infection with hepatitis C virus (HCV) is a significant risk factor and may be associated with inferior outcome.
- Conditions
- Hepatocellular Carcinoma, Ablation, Hepatitis C
- Trial name
- NCT05498779
- Testing
- Ablation therapy
- Where
- Denmark
- Volunteers
- 490 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chronic Hepatitis B
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
This is the first in human study of 162, and the primary objective is to evaluate the safety and tolerability of 162 with a single ascending dose in healthy adult subjects.
- Trial name
- NCT05310487
- Testing
- 162
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yangshengtang Co., Ltd
Hepatitis B, Chronic
A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine
A single center, open labeled phase I/IIa study to evaluate safety, tolerability and efficacy of a therapeutic hepatitis B vaccine in oral antiviral drug-treated chronic hepatitis B virus carriers
- Trial name
- NCT02693652
- Testing
- CVI-HBV-002
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Aribio Lab Co., Ltd.
Hepatitis B Virus
A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting
A Pharmacokinetics study of Baraclude in a real world clinical setting in Japan.
- Trial name
- NCT03083821
- Testing
- Baraclude
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment
- Trial name
- NCT03471624
- Testing
- Tenofovir Alafenamide
- Where
- 12 sites in United States, Japan and 2 more
- Volunteers
- 270 people
- Sponsor
- Stanford University
Hepatitis C Virus, HIV Infections
Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population
According to the centres taking part in the ALHICE survey, the number of HIV-HCV co-infected women is currently decreasing. This drop was first noted in 2006 and persisted in 2007.
- Conditions
- Hepatitis C Virus, HIV Infections, Pregnancy
- Trial name
- EPIALHICE B (NCT00894257)
- Where
- 3 sites in France
- Volunteers
- 142 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Hepatitis C
Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30%
The study aims to assess the impact of models of HCV care on HCV testing, treatment uptake and cure within Cairns. Point of care testing for HCV , with test and treat strategies will be offered within a primary care service.
- Trial name
- NCT05264558
- Testing
- Xpert HCV Viral load finger stick point of care test (Cepheid), Epclusa 400Mg-100Mg Tablet, Standard of care
- Where
- Australia
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Chronic Hepatitis B
Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B
This randomized controlled trial is designed to evaluate safety, effectiveness and pharmacokinetic-pharmacodynamic (PK/PD) relationships associated with three different Nitazoxanide (NTZ) treatment regimens added to Tenofovir…
- Trial name
- NCT03905655
- Testing
- Nitazoxanide
- Where
- Singapore
- Volunteers
- 51 people
- Sponsor
- Romark Laboratories L.C.
HIV-1-infection, Hepatitis B
B/F/TAF Switch Study for HIV-HBV Coinfection
The primary objective of this study is to evaluate the efficacy and safety of fixed dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults coinfected with both HIV-1 and hepatitis B.
- Trial name
- BEST-HBV (NCT03797014)
- Testing
- B/F/TAF
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Maryland, Baltimore
Hepatitis B, Chronic, Hepatic Steatosis
Aerobic Exercise Training in Patients With Chronic Hepatitis B and Hepatic Steatosis
This study is a randomised, controlled, unblinded, clinical intervention trial consisting of 12 weeks of aerobic exercise training.
- Trial name
- FitLiver (NCT05265026)
- Testing
- High Intensity Interval Training
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hepatitis C, Drug Use
DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)
The study aims to assess the effectiveness of a model of hepatitis C screening and integrated care, targeting people who inject drugs (PWIDs) in Hai Phong, Vietnam.
- Conditions
- Hepatitis C, Drug Use, Viral Hepatitis C
- Trial name
- DRIVE-C (NCT03537196)
- Testing
- Sofosbuvir 400 mg and Daclatasvir 60 mg, Sofosbuvir 400 mg and Daclatasvir 90 mg, Ribavirin
- Where
- 2 sites in Vietnam
- Volunteers
- 979 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Alcoholic Hepatitis
DUR-928 in Patients With Alcoholic Hepatitis
The proposed study is An Open-Label, Dose Escalation Study to Assess the Safety, and Pharmacodynamics (PD) signals of DUR 928 in Patients with AH.
- Trial name
- DUR-928/AH (NCT03917407)
- Testing
- DUR-928 (Moderate AH), DUR-928 (Severe AH)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Craig James McClain
Hepatitis C
Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy.
This study aims to evaluate the possible antifibrotic effect of zinc sulphate in chronic HCV patient receiving direct acting anti-viral therapy
- Trial name
- NCT05465434
- Testing
- Zinc Supplement
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
HBeAg-positive Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940471
- Testing
- TAF, TDF
- Where
- 160 sites in United States, Australia and 17 more
- Volunteers
- 875 people
- Sponsor
- Gilead Sciences
Hepatitis A
The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
The purpose of this Phase 4 trial is to assess the safety, immunogenicity, three-year immune persistence of inactivated hepatitis A vaccine (HAV) and live attenuated HAV vaccine.
- Trial name
- HAV (NCT01949857)
- Testing
- Attenuated HAV Vaccine, H2 Strain, Attenuated HAV Vaccine, L-A-1 Strain, Inactivated HAV Vaccine, Lu8 Strain
- Where
- China
- Volunteers
- 35,000 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Chronic Hepatitis B
A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors
This is a multicenter, randomized, controlled Phase IIa study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus.
- Trial name
- NCT05839639
- Testing
- NrtIs, HH-003, HH-003+NrtIs
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Huahui Health
HBeAg-negative Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940341
- Testing
- TAF, TDF
- Where
- 105 sites in United States, Australia and 15 more
- Volunteers
- 426 people
- Sponsor
- Gilead Sciences
Kidney Transplant, Hepatitis C
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
To evaluate the safety and feasibility of transplanting kidneys from Hepatitis C virus (HCV) infected donors into recipients without HCV infection
- Conditions
- Kidney Transplant, Hepatitis C, HCV
- Trial name
- NCT03801707
- Testing
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Ohio State University
Chronic Hepatitis B
A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects
This study is designed to assess safety, tolerability, and PK of single ascending doses (SAD) of ABI-4334 in Part A and multiple-ascending doses (MAD) of ABI-4334 in Part B in healthy subjects.
- Trial name
- NCT05569941
- Testing
- ABI-4334 Tablet
- Where
- New Zealand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences